Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet

Completed · Phase 1

Conditions studied: Anxiety Disorder

In brief

To assess if the sublingual tablet will have similar pharmacokinetics as the conventional tablet of alprazolam.

Key facts

Study ID

NCT01256151

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

28

Starts

2011-01-01

Expected to finish

2011-05-01

Last updated by the study team

2021-01-28

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.
• Signed informed consent.

You may not qualify if…

• Evidence or history of clinically significant abnormalities
• Positive drug screen, excessive alcohol and tobacco use

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.